Related Experiment Video

Updated: Jun 22, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

[New international guidelines on antithrombotic therapy in atrial fibrillation]

Arnljot Tveit1

  • 1Seksjon for indremedisinsk forskning, Medisinsk avdeling, Sykehuset Asker og Baerum, 1309 Rud. arnljot.tveit@sabhf.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|June 30, 2009
PubMed

Insights

New guidelines for atrial fibrillation antithrombotic therapy recommend warfarin for higher-risk patients. The CHADS2 score aids in stratifying stroke risk, improving treatment decisions for atrial fibrillation patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Practice Guidelines

Context:

  • International guidelines on antithrombotic therapy for atrial fibrillation have been revised.
  • These revisions may impact clinical practice in Norway.
  • Previous risk assessments for stroke in atrial fibrillation patients are being re-evaluated.

Purpose:

  • To discuss the potential impact of revised international guidelines on antithrombotic therapy in Norwegian clinical practice.
  • To analyze the role of the CHADS2 score in risk stratification for atrial fibrillation patients.

Summary:

  • Revised guidelines for atrial fibrillation antithrombotic therapy incorporate new findings on stroke risk.
  • The CHADS2 score (Congestive heart failure, Hypertension, Age, Diabetes, Stroke history) is recommended for warfarin decision-making.
  • Warfarin is advised for patients with a CHADS2 score of 2 or more, while aspirin or warfarin is suggested for a score of 1, and aspirin for a score of 0.

Impact:

  • The updated guidelines establish a higher threshold for prescribing warfarin in atrial fibrillation.
  • The CHADS2 score offers a reliable method for improved risk stratification.
  • Clinical practice in Norway may see adjustments in antithrombotic therapy recommendations for atrial fibrillation.
Abstract

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...